Net sales for FY2025 were JPY 241,236 million (up 1.7% YoY), operating income was JPY 4,163 million (down 13.1% YoY), and net loss attributable to owners of the parent was JPY 31,330 million (compared to a net profit of JPY 3,432 million in the previous year).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2590","jir_company_name":"DyDo Group Holdings, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/2590-20260304-02.pdf","jir_short_summary":"Net sales for FY2025 were JPY 241,236 million (up 1.7% YoY), operating income was JPY 4,163 million (down 13.1% YoY), and net loss attributable to owners of the parent was JPY 31,330 million (compared to a net profit of JPY 3,432 million in the previous year).","jir_summary":"### Overview of Performance\nConsolidated net sales for FY2025 reached JPY 241,236 million, representing a 1.7% increase year-over-year; however, operating income declined by 13.1% to JPY 4,163 million. Notably, net income attributable to owners of the parent plummeted from a profit of JPY 3,432 million in the previous year to a loss of JPY 31,330 million, significantly impacted by impairment losses amounting to JPY 29,826 million. Segment-wise, the domestic beverage business recorded net sales of JPY 142,651 million, a 3.3% decrease from the prior year, along with operating losses. Conversely, the overseas beverage business saw net sales rise 16.1% to JPY 65,341 million, also posting higher operating income. The rare disease pharmaceuticals business experienced substantial sales growth; however, losses continue. Capital expenditures increased to JPY 16,414 million, reflecting ongoing investments aimed at future growth.\n\n### Outlook and Challenges\nThe earnings forecast for FY2026 anticipates net sales of JPY 246,800 million, a 2.3% increase YoY, with a significant rise in operating income projected at JPY 10,500 million. The domestic beverage business is expected to return to profitability, while profit outlooks for the pharmaceutical-related and rare disease pharmaceuticals businesses are forecasted to decline. Continued impacts from hyperinflation accounting adjustments at the Turkish subsidiary have been factored in. Key challenges include improving the financial position and strengthening the earnings base.","jir_financial_highlights":"Net Sales: JPY 241,236 million (Up 1.7% YoY)\nOperating Income: JPY 4,163 million (Down 13.1% YoY)\nNet Loss Attributable to Owners of Parent: \u25b3JPY 31,330 million (Previous year recorded JPY 3,432 million profit)\nDomestic Beverage Business Net Sales: JPY 142,651 million (Down 3.3% YoY)\nOverseas Beverage Business Net Sales: JPY 65,341 million (Up 16.1% YoY)\nRare Disease Pharmaceuticals Business Net Sales: JPY 606 million (Up 6,645.5% YoY)\nCapital Expenditures: JPY 16,414 million (Up 15.2% YoY)","jir_category":"","jir_hashtags":"#DyDoGroupHoldings, #FinancialSupplement, #JapaneseStocks","jir_key_figures":"Net Sales: JPY 241,236 million (up 1.7% YoY)\nOperating Income: JPY 4,163 million (down 13.1% YoY)\nNet Loss Attributable to Owners of Parent: JPY 31,330 million (previous year recorded JPY 3,432 million profit)","jir_meta_title":"DyDo Group FY2025 Financial Supplementary Presentation | Net Sales JPY 241,236 Million, Operating Income JPY 4,163 Million","jir_meta_description":"DyDo Group Holdings' FY2025 financial supplementary presentation materials. Net sales grew 1.7% YoY to JPY 241,236 million, operating income declined 13.1% to JPY 4,163 million, and reported a net loss of JPY 31,330 million. Detailed segment trends and capital investment status are also explained.","jir_og_title":"DyDo Group Announces FY2025 Financial Supplementary Presentation Materials","jir_og_description":"Net sales for FY2025 were JPY 241,236 million, operating income was JPY 4,163 million, and net loss amounted to JPY 31,330 million. Detailed segment information and outlook provided.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend (FY2021\u2013FY2025)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2021\\\",\\\"FY2022\\\",\\\"FY2023\\\",\\\"FY2024\\\",\\\"FY2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales (million JPY)\\\",\\\"data\\\":[162602,160130,213370,237189,241236],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (FY2021\u2013FY2025)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2021\\\",\\\"FY2022\\\",\\\"FY2023\\\",\\\"FY2024\\\",\\\"FY2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (million JPY)\\\",\\\"data\\\":[4581,707,3732,4789,4163],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (FY2021\u2013FY2025)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2021\\\",\\\"FY2022\\\",\\\"FY2023\\\",\\\"FY2024\\\",\\\"FY2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income (million JPY)\\\",\\\"data\\\":[3974,-507,4423,3804,-31330],\\\"borderColor\\\":\\\"#3cba9f\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales Breakdown (FY2025)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Beverage Business\\\",\\\"Overseas Beverage Business\\\",\\\"Pharmaceutical-Related Business\\\",\\\"Food Business\\\",\\\"Rare Disease Pharmaceuticals Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales (million JPY)\\\",\\\"data\\\":[142651,65341,13435,19570,606],\\\"backgroundColor\\\":[\\\"#3e95cd\\\",\\\"#8e5ea2\\\",\\\"#3cba9f\\\",\\\"#e8c3b9\\\",\\\"#c45850\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_operating_profit_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Operating Income Breakdown (FY2025)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Beverage Business\\\",\\\"Overseas Beverage Business\\\",\\\"Pharmaceutical-Related Business\\\",\\\"Food Business\\\",\\\"Rare Disease Pharmaceuticals Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (million JPY)\\\",\\\"data\\\":[-2284,7547,829,487,-321],\\\"backgroundColor\\\":[\\\"#3e95cd\\\",\\\"#8e5ea2\\\",\\\"#3cba9f\\\",\\\"#e8c3b9\\\",\\\"#c45850\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"equipment_investment_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Capital Expenditures Trend (FY2021\u2013FY2025)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2021\\\",\\\"FY2022\\\",\\\"FY2023\\\",\\\"FY2024\\\",\\\"FY2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Capital Expenditures (million JPY)\\\",\\\"data\\\":[10064,11411,11593,14250,16414],\\\"borderColor\\\":\\\"#f39c12\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":16794,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-33146","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n